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Abstract
Background: The function of synaptotagmins (syt) in Ca
2+-dependent transmitter release has been attributed
primarily to Ca
2+-dependent isoforms such as syt I. Recently, syt IV, an inducible Ca
2+-independent isoform has
been implicated in transmitter release. We postulated that the effects of syt IV on transmitter release are
dependent on the expression of syt I.
Results: To test this, we increased syt IV expression in PC12 cells by either upregulation with forskolin treatment or
overexpression with transfection. Two separately generated stable PC12 cell lines with syt I expression abolished by
RNAi targeting were used and compared to control cells. We measured catecholamine release from single vesicles
by amperometry and neuropeptide Y release from populations of cells by an immunoassay. In syt I targeted cells
with forskolin-induced syt IV upregulation, amperometry measurements showed a reduction in the number of
release events and the total amount of transmitter molecules released per cell. In cells with syt IV overexpressed,
similar amperometry results were obtained, except that the rate of expansion for full fusion was slowed.
Neuropeptide Y (NPY) release from syt I knockdown cells was decreased, and overexpression of syt IV did not
rescue this effect.
Conclusions: These data support an inhibitory effect of syt IV on release of vesicles and their transmitter content.
The effect became more pronounced when syt I expression was abolished.
Background
Synaptic transmission is a highly regulated process that
relies on calcium (Ca
2+) to trigger the release of trans-
mitters from membrane bound vesicles. To accomplish
this fusion of vesicle and plasma membranes, the
SNARE (soluble NSF receptor) complex of proteins is
required as well as a Ca
2+ sensor that can bind Ca
2+
[1-4]. Synaptotagmin (syt) I is well established as a main
Ca
2+ sensor for rapid and regulated vesicle release from
neurons and neurosecretory cells [3,4]. It binds Ca
2+,
interacts with phospholipid membranes, and triggers the
SNARE complex proteins to allow vesicle fusion and
subsequent transmitter release [3,4].
Synaptotagmins are a conserved family of proteins
comprised of at least 17 different isoforms (see Pubmed
nucleotide ID# NM 138849, [5]). A distinguishing
feature of the syt isoforms is the tandem cytoplasmic C2
domains (C2A, C2B) that, for some isoforms, confer the
phospholipid and Ca
2+-binding ability to the specific iso-
forms [6-8]. Although syt isoforms share similar C2
domain structures, they differ in their ability to bind
Ca
2+ by the C2 domains. The Ca
2+-dependent syt iso-
forms bind to phospholipids as a function of Ca
2+-bind-
ing to the C2 domains and include syt I [7,9,10].
Conversely, syt IV is a unique syt isoform that has simi-
lar C2 domain structure, but does not bind Ca
2+ in the
C2A domain due to an amino acid substitution that pre-
vents Ca
2+-binding and presumably prevents the Ca
2
+-dependent functions attributed to the C2A domain
[6,7,10,11]. Unlike the C2A domain of syt IV, the C2B
domain is thought to retain the ability to bind Ca
2+, and
this binding of Ca
2+ to the C2B domains of other syt
isoforms has been shown to be essential for transmitter
release [12-14]. Therefore, controversy remains as to * Correspondence: harkinsa@slu.edu
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2+-dependent vesicle
fusion and subsequent transmitter release.
An intriguing feature of syt IV is that it is an immedi-
ate early gene whose expression is induced in vivo fol-
lowing treatment with kainic acid to induce seizures
[15]. In contrast, gene expression of syt I is either
unchanged or decreased with kainic acid treatment
[15-17]. Forskolin and depolarization with high K
+ leads
to increased syt IV expression in the neuroendocrine rat
pheochromocytoma (PC12) cells, mimicking the effects
of kainic acid [15,16]. In mice, lack of syt IV has been
associated with memory and performance deficits [18],
as well as depression-like behaviors [19]. These beha-
vioral effects in animals indicate that syt IV may play a
role in synaptic transmission, transmitter and/or vesicle
release processes.
Studies performed in PC12 cells and Drosophila have
shown that overexpression of syt IV decreases transmit-
ter release by the formation of hetero-oligomers with syt
I [20-22]. More recently, forskolin-induced syt IV
expression has been shown to decrease the fusion pore
stability that leads to a more readily closed fusion pore,
and thus, an increase in the frequency of ‘kiss and run’
events [23,24]. In syt IV knockout mice, vesicle release
from the posterior pituitary nerve terminals [25] and
hippocampal neurons [26] was enhanced compared to
wild type mice. Taken together, these results have con-
tributed to the hypothesis that syt IV acts to prevent
neurotransmitter release during periods of high stimula-
tion. However, in a separate study performed in mouse
hippocampal neurons, there were no measurable effects
of syt IV upregulation on fast synaptic transmission,
fusion modes or kinetics [27].
In Drosophila, syt IV has been shown to substitute for
syt I to mediate transmitter release [14], or in pituitary
gonadotropes, to be necessary for large dense core vesi-
cle (LDCV) release when syt I was not effective [28].
Furthermore, in glial cells, syt IV was shown to be
essential for Ca
2+-dependent release of glutamate
[14,29]. In most cases, experiments done to investigate
the involvement of syt IV on transmitter release were
performed in secretory cells that also expressed the pri-
mary Ca
2+-sensor, syt I. In fact, because syt IV has been
shown to co-localize with syt I and reported to form
hetero-oligomers [20-23,30-3 2 ] ,i ti sp o s s i b l et h a tt h e
function of syt IV in regulated release of vesicles is
dependent upon whether syt I is also expressed.
We hypothesize that syt IV modulates Ca
2+-regulated
transmitter release and that the function of syt IV is
dependent upon the presence of syt I. To test this
hypothesis, we used PC12 cell lines established pre-
viously in our laboratory. These cell lines have stable
incorporation of plasmid-based RNAi to specifically
eliminate expression of syt I [33]. We have already
shown that abolished syt I expression reduced catecho-
l a m i n e( C A )r e l e a s eb y~ 5 0 %from single cells [33].
Furthermore, we showed that evoked release of neuro-
peptide Y (NPY) from LDCVs was reduced in the
absence of syt I, establishing a role for syt I in differen-
tially regulating transmitter release from LDCVs com-
pared to small vesicles in PC12 cells [34]. In the current
study, we show that syt IV upregulation does not affect
CA release or NPY release when syt I is expressed.
However, upregulation of syt IV in the absence of syt I
expression reduces release of vesicles and their transmit-
ter content compared to release from cells that have
endogenous expression of syt IV with targeted knock-
down of syt I. Together, these data show that neither
upregulation nor overexpression of syt IV substitutes for
syt I.
Results
Expression of syt IV is upregulated by forskolin in syt I
knockdown cells
In a previous study, we established a PC12 cell line that
continuously expresses a short hairpin (sh)RNA
designed to silence expression of syt I, that we refer to
as shRNA-syt I (or shRNA-syt Ia if more than one
stable line was used) [33]. In that study, we showed that
expression of Ca
2+-dependent syt isoforms II, III, VII
and IX, and the SNARE proteins were unaltered by the
lack of syt I expression in the shRNA-syt I cells. How-
ever, we did not characterize the expression levels of syt
IV. Previously, other researchers had shown that syt IV
expression is rapidly increased in PC12 cells by treat-
ment with forskolin [15,35] which is thought to act on
adenylyl cyclase, a potent activator of cAMP production
that results in activation of multiple signal transduction
pathways including CREB-mediated transcription
[36,37]. It is postulated that forskolin-induced syt IV
expression is achieved by CREB-mediated transcription
[16]. Therefore, we treated control PC12 and syt I
knockdown cells with 50 μM forskolin, and used immu-
nodetection methods to determine whether upregulation
of syt IV expression was increased when cells have abol-
ished syt I expression [15,35].
Representative immunoblots of lysates prepared from
control PC12 and syt I knockdown cells show that syt
IV expression was induced within 2 hours of continuous
forskolin treatment. Figure 1A shows an example immu-
noblot of syt IV upregulation in response to forskolin
treatment measured from control PC12 cells normalized
to b-actin. Similar results were obtained in shRNA-syt I
cells. Intracellular cAMP was measured with an immu-
noassay, and increased approximately 200 to 300-fold in
each cell type as expected. The plots in Figures 1B and
C show the average fold increase in syt IV expression
levels measured in forskolin-treated control and
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cells. Densitometry analysis shows that syt IV expression
was significantly increased ~2.3-fold (n = 7) and peaked
after 4 hours of treatment with forskolin in control
PC12 cells compared to untreated cells (Figure 1B).
Likewise, syt IV expression in syt I knockdown cells
increased ~2.0-fold (n = 4) and peaked after 4 hours of
forskolin treatment (Figure 1C). These results are simi-
lar to previous reports that described an increase in syt
IV mRNA and protein expression within 4 hours of
treatment with forskolin [15,35]. We found similar
results in control transfected (CT, n = 4) cells that were
stably transfected with an empty plasmid that lacks a
targeting insert and does not express any shRNAs.
Furthermore, to be certain that upregulating syt IV does
not affect expression of syt I, we determined that syt I
expression was unaffected by forskolin treatment and
remained constant over time in forskolin-treated control
cells.
Upregulation of syt IV inhibits CA release in syt I
knockdown cells
To test the hypothesis that syt I and syt IV are function-
ally co-dependent in regulating exocytosis of transmitter
from vesicles, we used carbon-fiber amperometry to
detect the release of individual vesicles and secretion of
transmitter. We recorded amperometric release events
from control cells, shRNA-syt I knockdown cells, and
control transfected cells, each of which were either
untreated or treated with forskolin for 3-5 hours. Base-
line release was measured during the first 20-30 sec of
each recording while cells were continuously bathed in a
Hank’s Basal Salt Solution to establish the resting condi-
tions. The solution was then changed to a stimulating
solution of high K
+ (arrow in the amperometry traces,
Figures 2A-D, and 3B and 3C), and continuously per-
fused for 4 min. Figure 2 shows representative examples
of the recordings obtained from control PC12 cells com-
pared to cells treated with forskolin for 3-5 hours (Fig-
ures 2A and 2B). Figures 2C and 2D show examples of
amperometric recordings from syt I knockdown cells
compared to syt I knockdown cells treated with forsko-
lin. The syt I knockdown cell treated with forskolin (Fig-
ure 2D) exhibits reduced numbers of events compared
to the control, forskolin-treated cell (Figure 2B).
T h ep l o ti nF i g u r e2 Es h o w st h ea v e r a g en u m b e ro f
events per cell measured during the 4 min stimulation
period. There was no significant difference in the events
measured in forskolin-treated control cells compared to
untreated control cells. However, the average number of
events measured in forskolin-treated shRNA-syt I cells
was reduced by 84% compared to the number of events
measured in forskolin-treated control PC12 cells (p <
0.01). Furthermore, the average number of events in for-
skolin-treated syt I knockdown cells was significantly
reduced compared to the untreated syt I knockdown
cells. Therefore, when syt IV is upregulated with forsko-
lin, syt I functionally allows release of catecholamine-
containing vesicles; whereas, when syt I is abolished by
the shRNA targeting syt I, upregulation of syt IV causes
an even greater reduction in release events.
Stimulated influx of intracellular Ca
2+ is not reduced after
forskolin treatment in syt I knockdown cells
In addition to activating CREB-mediated transcription, in
some cells forskolin-induced cAMP production also leads
to release of Ca
2+ from intracellular stores [38]. We were
concerned that forskolin treatment could result in a sec-
ondary increase in intracellular Ca
2+ levels ([Ca
2+]i)a n d
induce transmitter release. To determine whether forsko-
lin treatment altered levels of intracellular [Ca
2+]i by
release of Ca
2+ from intracellular stores or influx of
extracellular Ca
2+,w eu s e df u r a - 2t oi m a g eC a
2+ and
measured relative levels of resting and stimulated [Ca
2+]i.
Figure 1 Synaptotagmin IV (syt IV) expression is increased by forskolin. Control and syt I knockdown cells were treated with 50 μM
forskolin (fsk) for 0, 2, 4 and 6 hours. (A) Immunoblot analysis shows that syt IV expression is upregulated after continuous fsk treatment for 4
hours in control PC12 cells. b-actin expression remained constant, and was used as a loading control. All lanes were loaded at 20 μg/lane. Syt IV
expression was normalized to arbitrary densitometry units of b-actin measured in control PC12 cells (B), n = 7, and in shRNA-syt I knockdown
cells (C), n = 4. Syt IV expressed peaked at 4 hours in both cell types (*p < 0.05).
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2+ levels in untreated and forskolin-treated
control, syt I knockdown and CT cells were unaffected
by forskolin-treatment (data not shown). With high K
+
stimulation, each group of cells responded with an
expected ~4-fold increase in [Ca
2+]i. Treatment with for-
skolin did not enhance or prevent influx of extracellular
Ca
2+ in response to depolarization in any of the cell
groups (data not shown). Thus, forskolin does not alter
extracellular Ca
2+ entering the cell, nor does it induce or
alter intracellular release of Ca
2+ f r o ms t o r e s .T h i si si n
agreement with previous results that show that some clo-
nal lines of PC12 cells do not have major intracellular
Ca
2+ stores [39,40], or that some PC12 cells lack the
receptors to activate release from stores [41].
Overexpression of syt IV confirms that syt IV inhibits CA
release in syt I knockdown cells
To determine that the reduced transmitter release was
specific to syt IV upregulation and not due to other
effects caused by forskolin-mediated cAMP production,
we transiently co-transfected the cells with two plas-
mids, one that expresses the human isoform of syt IV
and one that expresses enhanced green fluorescent pro-
tein (EGFP) in a 10:1 μg ratio, respectively. Transfec-
tions were performed in control PC12 cells and two
different, independent, stable syt I knockdown cell lines
(shRNA-syt Ia and Ib) that each had abolished expres-
sion of syt I. To determine that the exogenously
expressed syt IV protein was expressed in EGFP-expres-
sing PC12 cells, we used immunocytochemistry with an
anti-syt IV antibody that detects both human and rat syt
IV, and an antibody that detects EGFP. Figure 3A shows
untransfected (top) and co-transfected (bottom) PC12
cells stained for syt IV (red), EGFP (green), and nuclei
(blue). In the top images, the syt IV antibody shows that
syt IV is endogenously expressed at low levels in the
control PC12 cells. From an image analysis using ImageJ
software, the percentage of fluorescing pixels/cell was
measured from the red channel depicting syt IV expres-
sion and from the blue channel depicting the nuclei
stain. The ratio of the pixel percentages was compared
between the red and blue channels. In the lower images,
overexpressed syt IV is expressed at greater levels (~15-
fold) than endogenously expressed syt IV. A merge of
the red and green images shows that co-transfected cells
stained for both syt IV and EGFP. From three indepen-
dent experiments, we determined that nearly 100% of
the EGFP-expressing cells also stained for overexpressed
syt IV. Therefore, we were confident that when we
recorded from EGFP-expressing cells that those chosen
cells also overexpressed the plasmid expressing human
syt IV.
We used amperometry to measure individual release
events from the control and syt I knockdown cells that
Figure 2 Syt IV expression in syt I knockdown cells reduced
evoked secretion. Representative amperometry recordings are
shown from an untreated control cell (A), forskolin-treated control
cell (B), untreated shRNA-syt I knockdown cell (C), and a forskolin-
treated shRNA-syt I knockdown cell (D). The arrows depict where
the continuously perfused solution was changed from HBSS to 50
mM K
+ stimulating solution. (E) The average number of events per
cell group is shown in the plot for forskolin-treated control (n = 19),
shRNA-syt I knockdown (n = 16), and control transfected, CT (n =
12) cells, compared to untreated control (n = 24), shRNA-syt I
knockdown (n = 24) and CT (n = 15) cells (**p < 0.01).
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ure 3B shows an example amperometry recording from
a control cell (that endogenously expresses syt I) and
that has overexpressed syt IV. Figure 3C shows an
example recording of a syt I knockdown cell that has
overexpressed syt IV. After ~20 sec of baseline record-
ing, the solution was changed to a high K
+ stimulating
solution for 4 min (arrows in Figures 3B and 3C). The
plot in Figure 3D shows that the average number of
events per cell was reduced (p < 0.01) in the two inde-
pendent stable syt I knockdown cell lines (shRNA-syt Ia
and Ib, no syt IV expressed) compared to the non-trans-
fected control cells, as expected for cells that lack syt I.
There was also a reduction (p < 0.01) in the number of
events per cell between the control cells and syt I
knockdown cells (Ia and Ib) when syt IV was overex-
pressed. Although there was no difference in the average
number of events in control cells that express endogen-
ous levels of syt I when transfected with pSyt IV com-
pared to non-transfected cells (two leftmost bars), one
of the two syt I knockdown cell lines (Ib) showed a sig-
nificant decrease (p < 0.05) in the average number of
events when syt IV was overexpressed compared to
non-transfected syt Ib knockdown cells. The total num-
ber of events was reduced for the syt I knockdown cells
compared to control cells. The total number of events
was reduced further when syt IV was overexpressed
compared to the non-transfected cells. These numbers
Figure 3 Overexpression of syt IV has similar effects on secretion from the cells as upregulation of syt IV. (A) Confocal images of cells
are shown stained with fluorescently labeled antibodies to syt IV (red), EGFP (green), and nuclei (blue). The merge of all three images is shown
on the right. The top group of images shows endogenous staining for syt IV in control cells that have not been transfected with the plasmids
that express syt IV and EGFP. The lower group of images shows cells cotransfected with syt IV/EGFP plasmids in a 10:1 ratio. The images are
representative of 3 independent experiments (scale bar = 10 μm). (B) Amperometry recordings are shown in a representative control cell
transfected with the plasmid that expressed syt IV (pSyt IV) (C) and in an shRNA-syt I knockdown cell transfected with the pSyt IV (B). The arrows
depict where the continuously perfused solution was changed from HBSS to 50 mM K
+ stimulating solution. (D) The average number of events
is plotted for control cells (n = 16) and two independent stable syt I knockdown cell lines (syt Ia, n = 16, and syt Ib, n = 20) compared to cells
cotransfected with human syt IV/EGFP (control, n = 13 cells; syt Ia, n = 17 cells; and syt Ib, n = 17 cells; *p < 0.05 and **p < 0.01). (E) Basal and
stimulated norepinephrine (NE) release were analyzed from 9-21 independent experiments. NE release is expressed as total NE (ng) per 50 μl
sample (**p < 0.01).
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knockdown cells that had syt IV upregulated by
forskolin.
To confirm that the reduced number of release events
detected from individual cells was characteristic of the
population of forskolin-treated syt I knockdown cells,
high performance liquid chromatography-electrochemi-
cal detection (HPLC-EC) was used to measure norepi-
nephrine (NE) release from populations of cells. Figure
3E shows the amount of NE release detected from each
group of cells after 5 min of stimulation with high K
+.
There were no significant differences between control
and CT cells with or without forskolin treatment. Simi-
lar to the single vesicle release measurements detected
with amperometry, stimulated NE release was signifi-
cantly reduced (p < 0.01) in untreated syt I knockdown
cells compared to untreated control cells, as well as in
forskolin-treated syt I knockdown cells compared to for-
skolin-treated control cells. Stimulated release of NE
was decreased by half in forskolin-treated syt I knock-
down cells compared to untreated syt I knockdown cells
(p < 0.05).
Syt IV does not alter amplitude or quantal content of
vesicle release
Individual amperometric spike events can be analyzed
on expanded time scales to evaluate such parameters as
spike amplitude and quantal content that are correlated
to the amount of neurotransmitter molecules contained
within the vesicles [42]. Previously, others have deter-
m i n e dt h a tq u a n t a lc o n t e n ti sc o r r e l a t e dt ot h er e l a t i v e
diameter of the vesicle, with small events corresponding
to small vesicles, and larger events corresponding to
LDCVs [43]. Furthermore, analysis of the spike kinetics
describe the fusion pore expansion by the rate of rise,
and the half-width of the spike corresponds to the diffu-
sion of transmitter from the vesicle as the vesicle fuses
with the plasma membrane [44]. Quantitative analysis of
the amperometric spike shows that the mean peak
amplitude was similar in untreated and forskolin-treated
control cells, syt I knockdown cells and CT cells (Figure
4A). The integrated area under the spike events is calcu-
lated as the charge or quantal content per vesicle shown
in Figure 4B. There were no significant differences
regardless of forskolin-treatment in control and syt I
knockdown cells in the quantal content per vesicle
released. This indicates that the amount of transmitter
released per event was not different between the cells
that had syt IV upregulated or abolished syt I
expression.
A Gaussian distribution of measured quantal content
will depict the range of vesicle diameters released from
cells. Integrated charge over time (Q) is proportional to
vesicle volume assuming that transmitter concentration
is the same for all vesicles and that release of vesicle con-
tent results in complete emptying. Under these assump-
tions, the cubed root of the quantal charge (Q
1/3)i s
directly proportional to vesicle diameter [43,45]. To
determine whether a specific population of vesicles had
failed to be released from cells that had increased syt IV
expression, a cumulative distribution histogram of the
cubed root of quantal content (Q
1/3) was plotted versus
the number of events for all of the control and syt I
knockdown cells (Figure 5A-D). In each histogram
(where bin size was set to 48), the data for the untreated
control and forskolin-treated control cells are best
described by a single Gaussian. The means of the histo-
grams are shown on each plot, and are similar to one
another, ranging from 0.44 pC
1/3 to 0.51 pC
1/3.E a c ho f
the syt I knockdown cell groups, either with or without
forskolin treatment to upregulate syt IV, were similar to
control cells in their distribution of vesicle population.
However, the total number of events was largely reduced
in the syt I knockdown cells which affects the amplitude
of the distribution histogram. Because the means and dis-
tributions exhibit similar cubed roots of quantal content
(Q
1/3), there was no apparent loss of one population of
vesicles, only an apparent reduction in total number of
vesicles released from syt I knockdown cells.
Analysis of the amperometry events measured from
each type of cell with overexpressed syt IV had similar
peak amplitudes and quantal contents as the cells with
upregulated syt IV using forskolin. Additionally, the
cubed root of the quantal content and Gaussian histo-
grams gave similar ranges of means, and no apparent
loss of vesicle population. Therefore, in PC12 cells that
express endogenous syt I or cells stably transfected with
shRNA to target syt I knockdown, there is no difference
between averaged amplitudes or quantal content of
packaged transmitter when syt IV is upregulated or
overexpressed, nor is there any specific loss of one
population of vesicles for release compared to another,
such as small clear vesicles compared to LDCVs.
Overexpression of syt IV alters the fusion kinetics
We analyzed each of the release events measured from
the various groups of cells to determine whether the
properties of the fusion pore expansion and transmitter
diffusion were affected when syt IV expression was
upregulated by forskolin treatment, or overexpressed by
transfection, compared to control cells. There were no
differences in the half-width of the spikes for either the
upregulated syt IV or overexpressed syt IV. Figure 4C
shows the rate of rise (pA/ms) was significantly slowed
in both the control cells and the syt I knockdown cells
when syt IV was overexpressed, but not when syt IV
was upregulated with forskolin treatment. The rising
phase exhibited the same slowed kinetics. Therefore,
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expansion, but did not affect the rate of transmitter dif-
fusion from the vesicle (half-width).
Syt IV reduced the number of transmitter molecules
released from syt I knockdown cells
The Faraday equation, N = Qtot/ne, calculates the number
of oxidized CA molecules per cell (N) released, where
Qtot is total charge per cell, n is two electrons per oxi-
dized molecule of CA, and e is the elemental charge
(1.602 × 10
-19 C). For each cell, we calculated the total
charge per cell (Qtot) by multiplying the average charge
measured per vesicle (Q) by the total number of events
per cell. Tables 1 and 2 show the summary of the aver-
aged released number of CA molecules/cell for each
group. In Table 1, the number of molecules released
from untreated syt I knockdown cells were reduced com-
pared to the untreated control cells (p < 0.01), as were
the number of molecules released from forskolin-treated
syt I knockdown cells compared to forskolin-treated con-
trol cells (p < 0.01). Similar results are shown in Table 2
that compares the effects of overexpression of syt IV in
the syt I knockdown cells to control cells. To be certain
that the reduction in number of molecules in the syt I
knockdown cells were not due to a failure of the cells to
synthesize LDCVs, we confirmed that each of the groups
of cells contained LDCVs with electron microscopy (Fig-
ure 6A). However, without three-dimensional reconstruc-
tions of cells, it is not clear if there is a reduction in the
number of synthesized vesicles, or if LDCVs have a smal-
ler volume reflecting a possible reduced content of stored
CA. Even so, these data together indicate that syt IV does
n o ts u b s t i t u t ef o rs y tIt os u p p o r te v o k e dr e l e a s e ,b u t
instead, upregulation of syt IV expression further inhibits
release of vesicle contents.
Stimulated NPY release is not rescued by syt IV
The results described above summarize the effect of for-
skolin-induced syt IV expression on regulated CA
release in the presence and absence of syt I. CAs are
reported to be localized to both small vesicles and
LDCVs [46-48]. Previous reports show that syt IV is
localized to LDCVs and regulates the fusion mechanism
for LDCVs in syt I-expressing PC12 cells [23,24]. The
“core” of LDCVs is composed of many secretory pep-
tides including NPY [49,50]. Therefore, we tested
whether syt IV mediates the release of NPY from
LDCVs, and whether this is dependent upon the pre-
sence of syt I.
We used an immunoassay to measure stimulated NPY
release from control and syt I knockdown cells treated
with forskolin and compared to untreated cells. Figure
6B shows that NPY release was greatly reduced in two
independent syt I knockdown cell lines compared to
control cells. Both shRNA-syt Ia and Ic stable cell lines
exhibit reduced NPY release normalized to total protein
compared to control cells (p < 0.01). Similarly, in the
same cells that had upregulated syt IV expression fol-
lowing forskolin treatment, release of NPY remained sig-
nificantly reduced compared to control cells treated with
forskolin (p < 0.01). Reduced release of NPY was not
rescued by forskolin-upregulated syt IV expression.
Thus, syt IV does not act redundantly for syt I to
restore NPY release in syt I knockdown cells.
Discussion
In the current experiments, we have studied the role
that syt IV plays in regulating release of CAs and NPY
from vesicles without interference from the primary syt
isoform, syt I. Previously, we showed that syt I plays a
differential role in regulating release of these two
Figure 4 The rate of the fusion pore opening is slowed in syt I knockdown cells that overexpress syt IV, but neither the amplitude nor
quantal content of the individual release events are altered following syt IV upregulation. The ‘double’ means of the amplitude (A) and
quantal content (B) values are shown in bar histograms for forskolin-treated and untreated control, shRNA-syt I knockdown, and CT cells. (C) The
mean rate of rise (pA/ms) for each group of cells is plotted for the control and shRNA-syt I knockdown cells with control, endogenous levels of syt
IV expressed, upregulated syt IV expression by forskolin treatment, or overexpression of syt IV by transfection with pSyt IV (*p < 0.05, **p < 0.01).
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that express syt I, neither upregulated syt IV nor overex-
pressed syt IV affects the number of CA release events
measured from single cells (Figures 2E and 3D,
respectively), nor does syt IV affect CA release measured
from populations of cells by HPLC (Figure 3E). Simi-
larly, in cells that expressed syt I, there were no effects
of syt IV upregulation on NPY release (Figure 6B).
Figure 5 The overall number of events are reduced by syt IV upregulated in syt I targeted cells, but without any loss of the small or
large diameter vesicle populations. Cumulative distribution histograms of the cubed root of the quantal content (pC)
1/3 are shown for
untreated and forskolin-treated control (A, C) and shRNA-syt I knockdown (B, D) cells. The mean of each histogram is displayed on the individual
graph generated with 48 bins.
Table 1 CA molecules released from forskolin-treated control and shRNA-syt I knockdown cells
Average Number of CA Molecules/cell (× 10
6) ± SEM (× 10
6) Number of Cells
Control 47.5 ± 7.7 24
Fsk-Control 51.5 ± 8.3 19
shRNA-syt I 17.7 ± 3.1* 24
Fsk-shRNA-syt I 8.8 ± 1.9
+,± 16
The Faraday equation was used to calculate the average number of CA molecules per cell from the total charge per cell [44](*p < 0.01 compared to control cells;
+p < 0.01 compared to fsk-control cells; and
±p < 0.05 compared to shRNA-syt I cells).
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Page 8 of 14Conversely, in cells that had syt I expression abol-
ished, the number of CA release events was reduced
compared to control cells that endogenously expressed
b o t hs y tIa n dI V( F i g u r e s2 Ea n d3 D ) .I nt h es y tI
knockdown cells, increased syt IV expression resulted in
reduced CA release events. In a recent study by Arthur
et al. (2010), they speculated that syt IV knockout mice
have vesicles that are more fusogenic, which would sup-
port our finding that increased syt IV expression results
in less fusogenic vesicles. NPY release was also reduced
in these cells, but not reduced any more than what was
observed in cells that lacked syt I with endogenous syt
IV levels (Figure 6B). Previously, there was speculation
that syt IV mediates neuropeptide secretion from
LDCVs [31], however, we did not observe any rescue of
NPY release in cells that lacked syt I and expressed syt
IV (Figure 6B). Recently, in a study measuring exocyto-
sis of oxytocin and vasopressin, peptides secreted from
LDCVs from the posterior pituitary, syt IV was shown
to affect the Ca
2+ dependency for exocytosis [25]. In
that study, syt IV knockout mice responded to low
levels of Ca
2+ entry with greater exocytosis of vesicles,
and to higher levels of Ca
2+ with less exocytosis of vesi-
cles [25]. Therefore, in PC12 cells, syt IV plays an inhi-
bitory role in vesicle release that is revealed when syt I
is not expressed. Together, these data indicate that syt
IV does not substitute for syt I to support Ca
2+-depen-
dent release of transmitter from vesicles.
The average distribution of quantal content was mea-
sured for each of the upregulated syt IV and syt I
knockdown cells, and compared to control cells. From
the cubed root analysis of the average charge measured
per vesicle (Q) there was no apparent loss of one popu-
lation of vesicles over another based on means of the
distribution histograms in Figure 5, only an apparent
reduction in total number of vesicles released from syt I
knockdown cells. Average amplitude and charge per
vesicle are unaffected (Figures 4A and 4B, respectively).
The number of CA molecules released was not signifi-
cantly different when syt IV was upregulated or overex-
pressed in syt I expressing cells (Tables 1 and 2).
However, there was a reduction in number of CA
molecules released when control cells were compared to
syt I knockdown cells with endogenous expression of syt
IV (Tables 1 and 2). A similar reduction of CA mole-
cules released was observed for the control syt I knock-
down cells when syt IV expression was either
upregulated or overexpressed (Tables 1 and 2). Our
results agree with two previous studies that each used
overexpression of syt IV in PC12 cells in the presence of
syt I: a decreased number of transmitter molecules was
released [23], and many fewer vesicles were released
than from control cells without increasing extracellular
stimulation conditions [51].
Many possibilities could explain the reduced number
of CA molecules released from cells that have syt I
expression abolished and syt IV expression increased.
The first possibility is that forskolin treatment causes a
reduction of intracellular Ca
2+ i n f l u x ;h o w e v e r ,w e
report here that forskolin does not alter the influx of
intracellular Ca
2+ in any of the cell groups (data not
shown). A second possibility is that release of fewer CA
molecules is due to a reduction in the number of vesi-
cles synthesized. In fact, in a recent study from syt IV
knockout mice, synaptic vesicles were reduced in num-
bers synthesized, and in their targeting to proper release
sites [52]. We compared electron micrographs from
control and syt I knockdown cells that had endogenous
syt IV levels expressed or syt IV levels upregulated by
forskolin, and each cell group had LDCVs readily appar-
ent. Therefore, LDCVs were synthesized in each of the
cells; however, without serial reconstruction of the cells,
we cannot quantify or properly localize the vesicles to
address a possible reduction in total number of vesicles
synthesized. Furthermore, syt IV may be inhibiting Ca
2
+-triggered vesicle fusion mediated via the SNARE/phos-
pholipids, an effect that becomes more pronounced
when syt I is not expressed, thus revealing a role for syt
IV that is masked when syt I is expressed. Interestingly,
in a study using Drosophila neuromuscular junction,
evoked release could be inhibited by increasing the ratio
of syt IV to syt I expression [22].
We show that kinetic analysis of amperometric spikes
measured from both control and syt I knockdown cells
Table 2 CA molecules released from control and shRNA-syt I knockdown cells transfected with pSyt IV
Average Number of CA Molecules/cell (× 10
6) ± SEM (× 10
6) Number of Cells
Control 56.7 ± 7.2 16
pSyt IV-Control 64.3 ± 13.8 13
shRNA-syt Ia 16.0 ± 2.9** 16
pSyt IV-shRNA-syt Ia 11.1 ± 2.3
+ 17
shRNA-syt Ib 33.2 ± 7.8* 20
pSyt IV-shRNA-syt Ib 11.0 ± 2.4
+,± 17
The Faraday equation was used to calculate the average number of CA molecules per cell from the total charge per cell [44] (*p < 0.05 and **p < 0.01 compared
to control cells;
+p < 0.01 compared to pSyt IV control cells; and
±p < 0.05 compared to shRNA-syt Ib cells).
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Page 9 of 14that had overexpressed syt IV exhibited a reduced rate
of rise of the spike, indicating that expansion of the
fusion pore required a longer time to open to release
the transmitter contents compared to control cells (Fig-
ure 4C). Fusion kinetics were unaffected in either syt I
knockdown cells or control cells that had upregulated
syt IV expression. No other kinetic changes were
observed in any of the cell types with or without syt I
targeted or in cells with increased syt IV expression.
One possible explanation is that endogenous levels of
syt IV expression are relatively low until increased by
either forskolin treatment or overexpression. By overex-
pressing syt IV, we have bypassed the regulatory
machinery of syt IV expression and syt IV is constantly
expressed. Overexpression likely leads to unregulated
and possibly greater expression of syt IV than by forsko-
lin treatment, although because PC12 cells have low
transfection efficiency, it is difficult to quantify the levels
of overexpression of syt IV protein compared to upregu-
lation by forskolin using immunoblot analysis. In a study
in syt I-expressing hippocampal neurons that had over-
expressed syt IV, no changes in fusion kinetics were
observed [27], and in syt I-expressing PC12 cells that
had syt IV overexpressed, decreased fusion pore stability
was observed [23]. In our study, we have used the
human syt IV rather than rat syt IV for the overexpres-
sion studies. Even though the sequence is mostly con-
served, the human isoform may have somewhat
different Ca
2+ binding properties than the rat isoform,
which to our knowledge, has not been directly mea-
sured. However, differences in Ca
2+ binding affinities
have been reported in Drosophila, whose syt IV isoform
has been shown to have a higher affinity for Ca
2+ than
rat syt IV [53]. Unlike Drosophila syt IV, rat syt IV does
not participate in Ca
2+-dependent binding of phospholi-
pids [53,54]. Both homologues can form hetero-oligo-
mers with other syt isoforms [20,22]. Additionally, syt
IV has been shown to establish linear Ca
2+ dependence
of vesicle release from mouse auditory ribbon synapses
[55]. These results implicate syt IV as having a modula-
tory effect on vesicle release, that may be dependent
upon an expressed ratio of syt I and syt IV in different
vesicles, and at different synapses, an idea that was
confirmed in a Drosophila study [22].
Because PC12 cells normally express low levels of endo-
genous syt IV, syt I may dominate the phenotype and
therefore the function of syt IV by having a higher affinity
for Ca
2+ and therefore outcompeting endogenous levels of
syt IV for Ca
2+. Alternatively, because it has been shown
that syt I and IV colocalize at the same vesicles [23], by
knocking down expression of syt I, another mechanism
may become activated that compensates for syt I in the
release machinery which is the target for syt IV. This
observation would then become more apparent with an
increase of syt IV expression in the absence of syt I.
Conclusions
This study shows that syt IV inhibits release of transmit-
ters from PC12 cells that lack the primary Ca
2+ sensor,
Figure 6 LDCVs are synthesized and NPY release remains
reduced in shRNA-syt I knockdown cells when syt IV is
upregulated by forskolin treatment.( A) Large dense core vesicles
are apparent in both control and fsk-treated cells. Electron
micrographs reveal that in the control PC12 cells (top panels) and in
the syt I knockdown cells (lower panels), both untreated (left side)
and fsk-treated (right side) have large dense core vesicles (example
shown in each panel by arrowhead). Scale bar = 500 nm. (B) The
average stimulated NPY release from 9-12 independent experiments
is plotted. Untreated and forskolin-treated control cells, and two
independent syt I knockdown cell lines (shRNA-syt Ia and shRNA-syt
Ic) were stimulated for 15 min with high K
+ to evoke NPY release
(**p < 0.01).
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NPY release is reduced compared to control cells, and
that regardless of how syt IV expression is increased, syt
IV does not substitute to rescue the release. With the
development of the syt IV knockout mouse, others have
begun to determine how syt IV may function as a mod-
ulator of transmitter release. However, more studies are
needed to determine the exact mechanism of action of a
syt isoform that is Ca
2+-independent, but that in some
cases displays Ca
2+-dependent activities and promotes
release, while in other cases, acts to inhibit Ca
2+-depen-
dent transmitter release.
Methods
Antibodies
The anti-synaptotagmin IV goat polyclonal antibody was
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). The anti-b-actin mouse monoclonal antibody was
obtained from Developmental Studies Hybridoma Bank
(University of Iowa, Iowa city, IA).
Plasmids
A plasmid encoding human syt IV was constructed from
the pBluescriptR that contained the human syt IV DNA
construct (ATCC, Manassas, VA; GenBank ID: BC036538,
BI548768) and pcDNA 3.1 Neo (+) plasmid. The plasmid
was sequenced, and matched 100% the expected human
syt IV sequence. The EGFP-N1 plasmid was a kind gift
from Dr. William Green (University of Chicago).
Cell culture
An early passage of rat PC12 cells was maintained
according to standard methods [56,57]. Cells were pas-
saged every 7 days and after 10 passages, a new vial of
cells from frozen stocks was thawed. Stably transfected
cells were established as previously described [33,34].
For experiments that required forskolin treated cells,
cells were incubated with media containing 50 μMf o r -
skolin from 0 to 6 h as specified in the results. Prior to
experimentation, cells were plated to the appropriate
plates or coverslips, also coated with collagen.
Immunoblot analysis
Immunoblot experiments were performed as previously
described [33]. Briefly, cells were grown to confluency
on a 100-mm tissue culture dish, removed from plates
and lysed in buffer containing 20 mM Tris (pH = 7.5),
1% Triton-X 100, 10% glycerol, 2 mM EDTA, and pro-
tease inhibitor cocktail (Roche, Indianapolis, IN). Protein
concentration was determined by Coomassie Plus pro-
tein assay reagent (Pierce, Rockford, IL) or by the
Quant-iT protein assay with the Qubit fluorometric
method (Invitrogen-Molecular Probes, Carlsbad, CA).
Total cell lysates were electrophoresed on a 10%
NuPAGE Bis-Tris pre-cast gel (Invitrogen, Carlsbad,
CA) and transferred to a polyvinylidene difluoride mem-
brane (PVDF) (Millipore, Billerica, MA). The membrane
was blocked overnight with milk and incubated with pri-
mary antibody (1:1000 dilution), followed by a horserad-
ish peroxidase-conjugated secondary antibody (1:50,000
dilution, Santa Cruz Biotechnology, Santa Cruz, CA).
Immunoreactive bands were detected and visualized
using ECL Advance reagent (GE Healthcare, Piscataway,
NJ), exposed to X-ray film and developed. The blots
were stripped and reprobed for b-actin. Quantitative
analysis was done using Image J http://rsb.info.nih.gov/
ij/ to determine the relative amount of protein expres-
sion. Each immunoblot is representative of 3 or more
independent experiments.
Transfection
Cells were transfected with 3 μg of transfection grade
human syt IV plasmid DNA and EGFP-N1 plasmid
DNA at a 10:1 μg ratio per 35 mm tissue culture plates
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
The cells were incubated with the transfection mixture
for 4 hours. The cells were used in experiments 48
hours after transfection.
Immunocytochemistry
Cells were replated to collagen-treated Permonox cham-
ber slides and fixed one day later with 2% paraformalde-
hyde. The cells were permeabilized with 0.1% Triton X-
100, blocked with 2 mg/ml BSA, and incubated with a
p r i m a r ya n t i - s y tI Vg o a tp o l yclonal antibody (1:50 dilu-
tion). The cells were washed and incubated with a sec-
ond primary anti-EGFP Alexa Fluor-conjugated rabbit
polyclonal antibody (1:2,000; Invitrogen-Molecular
Probes, Carlsbad, CA). This was followed by incubation
with a secondary donkey-anti-goat Alexa Fluor-conju-
gated antibody (1:200; Invitrogen-Molecular Probes,
Carlsbad, CA) to detect syt IV. Nuclei were stained with
TO-PRO3 and the cells were mounted with Vectashield
(Vector Laboratories, Burlingame, CA). Images were
acquired using a scanning confocal microscope (Bio-Rad
MRC 1024; Hercules, CA) with a 4× zoom on a 60× oil-
immersion lens (NA 1.4).
Amperometry
Cells were replated to plastic sterile coverslips 24-48
hours prior to experimentation and preloaded with 2
mM norepinephrine (Sigma, St. Louis) for 2-5 hours at
37°C. Amperometric electrodes were fabricated by
threading a glass capillary tube with a 6 μm diameter
carbon-fiber (Goodfellow, Huntingdon, England). The
electrodes were pulled, sealed with epoxy, and stored at
95°C until use. The electrode was backfilled with 3 M
KCl, clamped at +700 mV versus a Ag-AgCl ground
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and placed adjacent to a cell to detect oxidized CA
transmitter. Recordings were collected from cells
e x p o s e dt oc o n s t a n ta n du n i f o r mp e r f u s i o n( ~ 1m l /
min). Cells were perfused for 5-10 min with Hank’s Buf-
fered Saline Solution (HBSS). Basal CA release was mea-
sured during the HBSS perfusion for ~20 sec prior to
changing to a high (50 mM) K
+ buffered saline solution
containing in mM: 50 KCl, 87 NaCl, 1 MgCl2, 5 CaCl2,
10 D-glucose, and 12 HEPES (pH = 7.3). Osmolarity of
both HBSS and the 50 mM K
+ solutions were matched.
Stimulated transmitter release was measured during the
remainder of the 4 min recording period. All experi-
ments were performed at ambient temperature, 22-24°C.
The amperometric signal was low-pass filtered at 2 kHz
(8-pole Bessel, Warner Instruments, Hamden, CT). A 16-
bit analog-to-digital converter (National Instruments,
Austin, TX) was interfaced with custom-written software
(graciously provided by Dr. Aaron P. Fox, University of
Chicago, Chicago, IL), acquired at 10 kHz and stored on
a personal computer. Root mean square (rms) noise was
typically less than 1 pA. Amperometric spike features
such as amplitude, quantal charge, and kinetic para-
meters were analyzed by custom-written analysis soft-
ware (graciously provided by Dr. Eugene Mosharov of
Columbia University, New York City, NY). The detection
threshold for an event was set for 5 times the baseline
rms noise level, and no trace was analyzed with rms
noise greater than 2.5 pA. Overlapping events, those
whose spike had not returned to baseline prior to the
next event, were not considered in the analysis even
though they were uncommon events. Rise time was mea-
sured over 25-75% of the spike’s maximal amplitude. The
area under individual amperometric spikes was measured
as the charge (Q measured in pC) per release event.
Statistical analysis of the spike events and kinetic
parameters was performed using the method described
by Colliver et al. [58]. To determine whether there
were any cells in a group that contained extreme
values, a ‘box and whiskers’ plot was generated using
the average peak amplitude, standard error and stan-
dard deviation from each cell in a group. Any cell with
a mean value that was not within the same range as
the majority of cells in a group was not considered for
further analysis. For the statistical analysis of each
kinetic parameter, the mean values for individual cells
were used to generate the average value for the group
o fc e l l s .T h i si sr e f e r r e dt oa st h e‘double mean’ and
was used to determine statistical significance by a t-
test with unequal variance.
Catecholamine analysis
CAs were identified and quantified by HPLC-EC as pre-
viously described [33,59,60]. Basal CA released was
collected from cells exposed to HBSS. Stimulated release
of CAs was collected from cells exposed to a stimulating
solution of 50 mM K
+. The samples were analyzed by a
system that consisted of a Varian Pro-Star solvent delivery
system and a model 9090 autosampler (Varian) coupled to
a C18 column and an ESA Coulochem II detector. Separa-
tions were performed isocratically using a filtered and
degassed mobile phase consisting of 12% methanol, 0.1 M
sodium phosphate, 0.2 mM sodium octyl sulfate and 0.1
mM EDTA, adjusted to pH 2.7 with phosphoric acid. A
computer was used to collect and store the chromato-
grams that were analyzed with Varian Star software.
NPY analysis
Cells and samples were prepared and treated similarly for
basal and stimulated release of NPY as for CAs except
cells were stimulated for 15 min to evoke measurable
NPY release, as previously determined for the optimal
time course for stimulated NPY release [61]. NPY in the
samples was purified with C18 Sep-Pak columns, (Penin-
sula Labs; San Carlos, CA) measured by an enzyme
immunoassay and compared to a standard curve. The
96-well plate was read by a Powerwave × plate reader
(Biotek instruments; Winooski, VT) and the calculation
of sample value was analyzed by KC Junior Software
(Biotek instruments). Basal and stimulated NPY release
were normalized to total protein content determined by a
BCA protein concentration assay (Pierce, Rockford, IL).
Ca
2+ imaging
Intracellular Ca
2+ concentrations ([Ca
2+]i) were mea-
sured using ratiometric fluorescence imaging with fura-2
(InCytIM2, Intracellular Imaging, Cincinnati, OH). Cells
were replated 24 h before experimentation, loaded with
fura-2, and prepared for recording as previously
described [33,62]. Cells were washed for ~10 min prior
to experimentation with HBSS while the cells were indi-
vidually selected with imaging software. On each cover-
slip, 20-40 cells were individually imaged. Image pairs
were obtained every 10 seconds at 340 nm and 380 nm
wavelength. Backgrounds were subtracted from each
wavelength, and the 340 nm image was divided by the
380 nm image to provide a ratiometric image. Ratios
were converted to free [Ca
2+]i by comparing data to
fura-2 calibration curves made in vitro by adding fura-2
(50 μM free acid) to solutions that contained known
[Ca
2+] (0 nM to 602 nM; Molecular Probes-Invitrogen,
Carlsbad, CA). Average resting and stimulated [Ca
2+]i
were determined from numerous independent experi-
ments. Resting [Ca
2+]i was measured during the first
180 sec of recording prior to stimulation with a high K
+
solution. Stimulated [Ca
2+]i was calculated from the five
points during the peak change in Ca
2+ levels that
occurred in response to stimulation.
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Page 12 of 14Electron Microscopy
Cells that were untreated or forskolin-treated for 4 hrs
were pelleted by centrifugation and fixed with ice-cold
3.5% glutaraldehyde in 0.1 mol/L sodium cacodylate
buffer (pH 7.25) containing 5% sucrose and 2 mmol/L
calcium chloride for 16 hours at 4°C. Cell pellets were
washed in 0.1 mol/L sodium cacodylate buffer contain-
ing 5% sucrose (this and all subsequent steps up to
polymerization were at room temperature) and post-
f i x e di n1 %o s m i u mt e t r o x i d ei n0 . 1m o l / Ls o d i u m
cacodylate buffer containing 5% sucrose for 3 hours.
Cell pellets were then washed twice in distilled water,
incubated for 1 hour in 2% aqueous uranyl acetate,
dehydrated through graded ethanols to 100%, rinsed
twice in propylene oxide, and infiltrated with a 1:1 mix-
ture of Polybed resin (Polysciences, Inc., Warrington,
PA) and propylene oxide for 3 hours. The cell pellets
were then incubated in fresh Polybed resin for 3 hours,
transferred to BEEM capsules filled with fresh resin,
and polymerized overnight at 70°C. Ultrathin sections
(0.05 μm) were cut with a diamond knife using a Reich-
ert Ultracut E ultramicrotome (Depew, NY), collected
on 200 mesh copper grids, post stained with uranyl
acetate and lead citrate, and viewed and photographed
with a JEOL (Peabody, MA) 100CX transmission elec-
tron microscope.
Statistical analysis
All data are displayed as mean ± SEM. Statistical signifi-
cance was determined by a t-test with unequal variance.
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